Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchMontelukastMontelukast (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Montelukast for COVID-19
8 studies from 87 scientists
2,868 patients in 7 countries
Statistically significant lower risk for mortality, hospitalization, and cases.
4 studies from 4 independent teams in 4 countries show significant improvements.
COVID-19 Montelukast studies. Jun 2024. c19early.org
0 0.5 1 1.5+ All studies 40% Mortality 92% Hospitalization 17% Recovery 23% Cases 82% RCTs 39% Prophylaxis 64% Late 42% Favorsmontelukast Favorscontrol
Home   Post   Share   @CovidAnalysis   Meta AnalysisMeta   Montelukast has a boxed warning for neuropsychiatric side effects fda.gov. Recent:
Mulgaonkar
Camera
Alhmoud
Kumar
Barré
Bozek
May.
Submit updates/corrections. Summary.
Jun 13
Covid Analysis Montelukast for COVID-19: real-time meta analysis of 8 studies
Statistically significant lower risk is seen for mortality, hospitalization, and cases. 4 studies from 4 independent teams in 4 countries show significant improvements. Meta analysis using the most serious outcome reported shows..
May 18
Rothman et al., medRxiv, doi:10.1101/2024.05.16.24307115 Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial
1% fewer combined hospitalization/ER visits (p=1), 32% lower progression (p=0.29), and 2% improved recovery (p=0.71). RCT 1,250 outpatients with mild to moderate COVID-19 showing no significant difference in time to sustained recovery with montelukast treatment. There were no deaths and only 2 hospitalizations in each group. Notably, results were better ..
Sep 23
2023
Alhmoud et al., Qatar Medical Journal, doi:10.5339/qmj.2023.15 Characteristics and outcomes of adult patients with asthma presenting with COVID-19: A comparative cohort study
13% lower hospitalization (p=0.61). Retrospective 616 COVID-19 patients with asthma in Qatar showing no significant difference in hospitalization risk with montelukast use.
Aug 31
2023
Cordero et al., NCT04695704 Double-blind Randomized Clinical Trial, Placebo-controlled to Assess the Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19: E-SPERANZA COVID-19 PROJECT
Estimated 284 patient montelukast late treatment RCT with results not reported over 9 months after estimated completion.
Jul 5
2023
Mulgaonkar et al., Pharmaceutics, doi:10.3390/pharmaceutics15071891 Montelukast and Telmisartan as Inhibitors of SARS-CoV-2 Omicron Variant
In Silico and In Vitro study showing that montelukast and telmisartan inhibit SARS-CoV-2 wild-type and the omicron variant. In Silico analysis found montelukast and telmisartan bind to the SARS-CoV-2 spike protein receptor binding domain ..
Mar 30
2023
Salehi-Pourmehr et al., Biomedical Research Bulletin, doi:10.34172/biomedrb.2023.06 Effect of Montelukast on Treatment of Coronavirus Pneumonia (COVID-19): A Systematic Review
Systematic review of 8 studies showing improved symptoms, clinical deterioration, hospitalization length, and mortality with montelukast treatment for COVID-19 patients.
Sep 15
2022
Mohamed Hussein et al., The Egyptian Journal of Bronchology, doi:10.1186/s43168-022-00154-6 Value of montelukast as a potential treatment of post-COVID-19 persistent cough: a non-randomized controlled pilot study
50% improved recovery (p<0.0001). RCT 68 post-COVID-19 outpatients showing improvement in cough severity measures with montelukast treatment. The montelukast group had a greater reduction in number of cough paroxysms per day, cough severity visual analog scale, cough seve..
Jul 31
2022
Soltani et al., The Clinical Respiratory Journal, doi:10.1111/crj.13529 The effectiveness of gabapentin and gabapentin/montelukast combination compared with dextromethorphan in the improvement of COVID‐19‐ related cough: A randomized, controlled clinical trial
20% shorter hospitalization (p=0.01) and 25% improved recovery (p=0.0006). RCT 180 hospitalized COVID-19 patients showing improved cough frequency and severity with gabapentin and gabapentin/montelukast compared to dextromethorphan, with the combination being more efficacious. The gabapentin/montelukast group ha..
Jun 1
2022
Durdagi et al., NCT04718285 A National, Multi-Center, Open-Label, Three-Arm, Phase II Study to Investigate the Effect of Montelukast Between Emergency Room Visits and Hospitalizations in COVID-19 Pneumonia in Comparison With Standard Treatment
Estimated 380 patient montelukast early treatment RCT with results not reported over 2 years after estimated completion.
Feb 28
2022
May et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.108412 Levocetirizine and montelukast in the COVID-19 treatment paradigm
Retrospective 53 patients reporting a potential benefit with levocetirizine and montelukast treatment for COVID-19. 51 of 53 patients were considered clinically cured on the combination therapy, with symptom resolution typically within 7 ..
Feb 8
2022
Camera et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.784214 Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients
In Vitro study showing that montelukast inhibits platelet activation induced by plasma from COVID-19 patients. Authors demonstrate that montelukast prevents the surface expression of tissue factor (TF) and P-selectin on platelets, reduces..
Jan 4
2022
Kerget et al., Journal of Medical Virology, doi:10.1002/jmv.27552 Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID‐19
92% lower mortality (p=0.01), 81% lower progression (p=0.007), and 15% shorter hospitalization (p=0.04). RCT 180 hospitalized COVID-19 patients in Turkey showing faster reduction in inflammatory markers, improved pulmonary function, and lower rates of macrophage activation syndrome, respiratory failure and mortality with montelukast treatmen..
Nov 22
2021
Kumar et al., International Journal of Basic & Clinical Pharmacology, doi:10.18203/2319-2003.ijbcp20214502 Efficacy of montelukast in the management of COVID-19: double blind randomized placebo controlled trial
67% lower ICU admission (p=0.62), 25% higher progression (p=0.79), and no change in hospital discharge (p=1). RCT 90 mild to moderate COVID-19 patients showing no significant differences with montelukast treatment.
Mar 4
2021
Khan et al., Journal of Asthma, doi:10.1080/02770903.2021.1881967 Montelukast in hospitalized patients diagnosed with COVID-19
64% lower progression (p=0.09) and 12% shorter hospitalization (p=0.33). Retrospective 92 hospitalized patients showing lower clinical deterioration with montelukast treatment, without statistical significance in multivariable analysis. The treatment group was older.
Feb 10
2021
Lima-Morales et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.02.014 Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico
78% lower mortality (p=0.001), 52% lower ventilation (p=0.15), 67% lower hospitalization (p=0.001), and 59% improved recovery (p=0.001). Prospective trial of 768 COVID-19 outpatients in Mexico, 481 treated with ivermectin, AZ, montelukast, and aspirin, and 287 control patients with various treatments, showing significantly lower mortality and hospitalization, and significa..
Sep 17
2020
Bozek et al., Journal of Asthma, doi:10.1080/02770903.2020.1786112 Montelukast’s ability to fight COVID-19 infection
91% lower hospitalization (p=0.02) and 82% fewer cases (p=0.004). Retrospective 445 elderly patients with severe asthma showing reduced risk of COVID-19 infection with montelukast treatment.
Sep 4
2020
Barré et al., Frontiers in Pharmacology, doi:10.3389/fphar.2020.01344 Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence
Review of evidence that montelukast may improve COVID-19 prognosis. Authors note ten experimentally supported properties of montelukast that could be beneficial, including antiviral effects, prevention of SARS-CoV-2-induced endotheliitis ..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit